Back to Rankings

ENOV

EnovisB
NYSE / Health Care Equipment & Services
Last Price
At close
2026-07-20
View Chart
Current thesis
The bull case is that investors eventually focus on the underlying operating picture rather than the goodwill write-down: FY2025 organic growth was 6%, Recon remained the stronger segment, and 2026 guidance implies another year of growth and EBITDA expansion if execution holds [#8-K-2026-02-26].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Execution miss versus 2026 organic growth, EBITDA, or EPS guidance could quickly reopen downside.
Momentum
57
Value
60
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $28.00 · Bull $36.00 · Bear $18.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-22 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $40.73
Why
Momentum57 · Δ7d +33.0
Value60 · Δ7d -0.2
Sentiment54 · Δ7d -9.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
57
26% active weight
Current posture
7d trendImproving
Δ7d
+33.0
Δ21d
+36.9
Value
60
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-1.1
Sentiment
54
34% active weight
Current posture
7d trendSoftening
Δ7d
-9.0
Δ21d
-20.7
Why this grade

Composite grade B. Momentum 56.6 / Value 59.5 / Sentiment 54.2

Fundamentals (TTM)
As of 2026-07-20
Market Cap
$1.54B
Beta
1.29
Shares Out
57.56M
P/E (TTM) · Derived
-1.3
P/S (TTM)
0.69
P/FCF (TTM)
67.85
Rev YoY
+5.4%
EPS YoY
-84.5%
Gross Margin
+52.6%
Op Margin
-57.7%
Net Debt
$1.34B
Current Ratio
2.04
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology